Target intelligence / Profile preview

Nuclear protein 2, transcriptional regulator (NUPR2)

Target
NUPR2
Molecular classification
Transcription factor, Other (nuclear stress protein, negative regulator of another transcription factor)
01

Overview

Nuclear protein 2, transcriptional regulator (NUPR2), also called nuclear protein 1-like (NUPR1L) or P8, is a small nuclear transcription factor involved in the negative regulation of cell proliferation and transcription[3]. It functions as a transcriptional repressor with inhibitory effects at the NUPR1 promoter in a p53-dependent manner, leading to G1 cell cycle arrest and reduced cell viability[3][6]. NUPR2 mutually antagonizes NUPR1, a protumoral factor, and is itself regulated by p53 responsive elements—its expression rises with stress conditions such as serum starvation and is reduced by NUPR1 activity[6]. Unlike NUPR1, which is pro-oncogenic, NUPR2 exhibits tumor-suppressive properties in some contexts (e.g., colorectal cancer cells)[6]. NUPR2 binds known NUPR1 partners (including RING1B) and can form complexes with NUPR1. NUPR2 is associated with Dyskeratosis Congenita and may play roles in stress regulation beyond cancer, but direct evidence for targeting or therapeutic intervention is lacking[3][6].

Other names
NUPR1LP8Nuclear transcriptional regulator 1-like proteinNuclear transcriptional regulator protein 2Nuclear protein 2Nuclear protein, transcriptional regulator, 1-like
02

Biological functions

Negative regulation of cell proliferationTranscriptional repression (notably at the NUPR1 promoter)Cell cycle arrest (G1 phase)Cellular response to starvation and stressNegative regulation of transcription by RNA polymerase II
03

Disease associations

Cancer (inhibitory role in colorectal cancer; antagonist to NUPR1, which is oncogenic)Possibly implicated in Dyskeratosis Congenita
04

Safety considerations

None documented in relation to NUPR2 drug targeting or inhibition. Safety concerns might arise indirectly due to modulation of cell cycle or interaction with stress response, but not therapeutically established[6].
05

Biomarkers

No validated biomarkers for patient selection or monitoring as pertains specifically to NUPR2.NUPR2 might serve as a negative regulator impacting NUPR1-associated pathways, but no clinical biomarker status is apparent[6].

Beyond the preview

Go deeper on Nuclear protein 2, transcriptional regulator (NUPR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear protein 2, transcriptional regulator (NUPR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call